Peripheral Arterial Disease (PAD) Therapeutics Global Strategic Research Report 2024
March 01, 2024 06:43 ET
|
Research and Markets
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Peripheral Arterial Disease (PAD) Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global...
Critical Limb Ischemia Treatment Market to Exceed US$ 3.49 Bn by 2031: TMR Study
August 17, 2022 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - Advancements in endovascular techniques and optimal revascularization techniques are some...
Two-year data from the TOBA II BTK clinical trial demonstrate durability of dissection repair below the knee with the Philips Tack Endovascular System
June 03, 2021 14:40 ET
|
Royal Philips
June 3, 2021 Results show that first-of-its-kind device has a sustained treatment effect and a positive impact on quality of life Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,...
UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
January 14, 2020 08:05 ET
|
Cynata Therapeutics Limited
MELBOURNE, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has...
Cynata Receives Favourable Advice from UK MHRA on CLI Clinical Trial
March 12, 2019 09:03 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, March 12, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that...
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
February 25, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC...
Hemostemix Announces Submission of Orphan Drug Designation Application to the FDA
February 04, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing...
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
January 03, 2019 08:00 ET
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two...
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
November 09, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and...
Hemostemix Announces Important Manufacturing Process Refinements
November 08, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that is has completed refinements to its...